• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Animal Health

Penn Medicine launches a pioneering project to study the human virome puzzle

January 14, 2025 Microbiome Times

For over a decade, scientists have studied the microbiome, the environment of microorganisms that live on and in the body, and how it affects health and disease. Much less is known about a part of […]

Editor's Choice

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

January 8, 2025 Microbiome Times

MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]

Pharma & Human Health

A new way to determine whether a species will successfully invade an ecosystem

January 7, 2025 Microbiome Times

When a new species is introduced into an ecosystem, it may succeed in establishing itself, or it may fail to gain a foothold and die out. Physicists at MIT have now devised a formula that […]

Pharma & Human Health

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

December 17, 2024 Microbiome Times

Antibiotics are important clinical tools for treating bacterial infections, yet we recognize that an important side effect of antibiotic use is disruption of the microbial community living in the human gut. Antibiotics targeted against bacterial […]

Pharma & Human Health

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

December 17, 2024 Microbiome Times

Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the […]

Pharma & Human Health

Possible colon cancer vaccine target uncovered in bacteria

December 12, 2024 Microbiome Times

Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and […]

Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

December 10, 2024 Microbiome Times

Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]

Finance

UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies

December 2, 2024 Microbiome Times

Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech […]

Pharma & Human Health

A new simple and effective tool that recommends the best possible phage cocktail for a given patient

November 28, 2024 Microbiome Times

With the rapid development of antibiotics in the 1930s, phage therapy – using viruses known as bacteriophages or phages to tackle bacterial infections – fell into oblivion. But as the current rise in antibiotic resistance […]

Finance

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science

November 19, 2024 Microbiome Times

Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under […]

Finance

Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation

November 19, 2024 Microbiome Times

The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation […]

Posts navigation

« 1 … 4 5 6 … 77 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter